Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailOral antifungal-exacerbated inflammatory flare-up reactions of dermatomycosis: Case reports and review of the literature
Nikkels, Arjen ULg; Tassoudji, Nazli ULg; Pierard, Gérald ULg

in American Journal of Clinical Dermatology (2006), 7(5), 327-331

Inflammatory flare-up reactions of some dermatomycoses, particularly those caused by zoophilic fungi, are typical and potentially severe adverse effects following the intake of some oral antifungals ... [more ▼]

Inflammatory flare-up reactions of some dermatomycoses, particularly those caused by zoophilic fungi, are typical and potentially severe adverse effects following the intake of some oral antifungals. However, this condition has not previously been reported with the most frequently used antifungals in dermatology, namely fluconazole, itraconazole, and terbinafine. In this report, we describe five patients, observed over a 10-year period, who presented with inflammatory exacerbations following oral antifungal therapy for dermatomycoses. We also review the literature on inflammatory reactions exacerbated by oral antifungal agents. Details of the patients' age, sex, occupation, and atopic background; the site of the lesion, its clinical and histologic features, and any systemic signs; the identity of the fungal pathogen; the antifungal agent taken by the patient; the time between drug intake and occurrence of the flare-up; the approach to management; and the outcome were documented for each patient. A PubMed literature search was also conducted, focusing on inflammatory exacerbations induced by griseofulvin, ketoconazole, itraconazole, fluconazole, and terbinafine. The patients were four farmers and one veterinarian (all male). All primary lesions were inflammatory dermatophytoses, including one kerion. Inflammatory exacerbation of the skin lesions started 12-24 hours after the intake of oral antifungals. Mild systemic changes, including slight fever and malaise, occurred in two cases. Itraconazole 400 mg/day was implicated as the causative agent in four cases and terbinafine 250 mg/day in one case. Mycologic cultures grew Trichophyton verrucosum in four cases. Antifungal treatment was discontinued in all patients. Oral and topical corticosteroids were administered to the two patients with systemic changes; the other three patients were treated with topical corticosteroids only. Two days after the onset of corticosteroids, lower doses of itraconazole (100 mg/day) and terbinafine (125 mg/day) were reintroduced. All lesions healed after 4-5 weeks. The PubMed search did not identify any articles that described inflammatory exacerbations of dermatomycoses induced by oral antifungals. Inflammatory flare-up of der-matomycoses is a rare but potentially severe cutaneous complication of oral antifungal use. Occupational contact with animals, inflammatory dermatomycoses, and zoophilic fungi represent common features in these patients. Although evidence-based data are not available, clinical experience shows that, in addition to antifungal therapy, topical and/or systemic corticosteroids are helpful to reduce the inflammatory reactions. The cases described in this article represent the first published report of oral antifungal-exacerbated inflammatory flare-up reactions of dermatomycosis in patients taking itraconazole or terbinafine. [less ▲]

Detailed reference viewed: 38 (3 ULg)
Full Text
Peer Reviewed
See detailOral antivirals revisited in the treatment of herpes zoster: what do they accomplish?
Nikkels, Arjen ULg; Pierard, Gérald ULg

in American Journal of Clinical Dermatology (2002), 3(9), 591-8

Oral antiviral agents currently represent the most important therapeutic keystone in the treatment of herpes zoster. Three oral antiviral agents are available for the treatment of herpes zoster: acyclovir ... [more ▼]

Oral antiviral agents currently represent the most important therapeutic keystone in the treatment of herpes zoster. Three oral antiviral agents are available for the treatment of herpes zoster: acyclovir, its derivative valacyclovir, and famciclovir. Meta-analysis of published data has shown that oral acyclovir significantly reduces various herpes zoster-related symptoms as well as the duration, intensity and prevalence of zoster-associated pain (ZAP). However, this drug does not influence postherpetic neuralgia. The newer agents famciclovir and valacyclovir exhibit a better oral bioavailability than acyclovir. These agents have demonstrated similar efficacy to acyclovir with ZAP and they require less frequent administration. When initiated within 72 hours, oral antiviral therapy of herpes zoster is beneficial in selected, elderly immunocompetent patients, reducing the duration and intensity of ZAP and providing more rapid skin lesion healing. Oral antivirals are also of benefit in immunocompromised patients with uncomplicated herpes zoster. However, signs of cutaneous and visceral dissemination should be monitored; if signs occur, intravenous antiviral therapy is indicated. [less ▲]

Detailed reference viewed: 25 (4 ULg)
See detailL'oral au quotidien : pistes de réflexion et d'action pour l'enseignement du langage oral au cycle 2 ans 1/2 à 5 ans.
Hindryckx, Geneviève ULg

Book published by Centre technique et pédagogique de la Communauté française (2006)

Detailed reference viewed: 74 (8 ULg)
Full Text
Peer Reviewed
See detailOral bioavailability in pigs of a miconazole/hydroxypropyl-gamma-cyclodextrin/L-tartaric acid inclusion complex produced by supercritical carbon dioxide processing
Barillaro, Valery; Evrard, Brigitte ULg; Delattre, Luc ULg et al

in AAPS Journal (2005), 7(1), 149-155

The objective of this study was to determine the pharmacokinetic parameters of miconazole after oral administration of a miconazole/hydroxypropyl-gamma-cyclodextrin(HPgammaCD)/L-tartaric acid inclusion ... [more ▼]

The objective of this study was to determine the pharmacokinetic parameters of miconazole after oral administration of a miconazole/hydroxypropyl-gamma-cyclodextrin(HPgammaCD)/L-tartaric acid inclusion complex produced by supercritical carbon dioxide processing. The pharmacokinetics of the miconazole ternary complex (CPLX), of the corresponding physical mixture (PHYS), and of miconazole alone (MICO) were compared after oral administration. Six mixed-breed pigs received each formulation as a single dose (10 mg miconazole/kg) in a crossover design. Miconazole plasma concentrations were determined by a high-performance liquid chromatography method. Preliminary in vitro dissolution data showed that CPLX exhibits a faster and higher dissolution rate than either PHYS or MICO. Following CPLX oral administration, mean area under the plasma concentration curve (AUC(0-infinity)) for miconazole was 95.0 +/- 55.8 microg/min/mL, with the peak plasma concentration (C(max) 0.59 +/- 0.39 microg/mL) at 19.30 minutes. The AUC(0-infinity) and C(max) values were significantly higher than those after oral administration of PHYS (AUC(0-infinity) 38.5 +/- 12.7 microg/min/mL and C(max) 0.24 +/- 0.08 microg/mL; P < .1) and of MICO (AUC(0-infinity) 24.1 +/- 14.0 microg/min/mL and C(max) 0.1 +/- 0.05 microg/mL; P < .1). There were also significant differences between PHYS and MICO (P < .1). The results of the study indicate that CPLX shows improved dissolution properties and a higher relative oral bioavailability compared with PHYS and MICO. [less ▲]

Detailed reference viewed: 47 (3 ULg)
Full Text
Peer Reviewed
See detailOral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-beta-cyclodextrin
Evrard, Brigitte ULg; Chiap, Patrice ULg; De Tullio, Pascal ULg et al

in Journal of Controlled Release (2002), 85(1-3), 45-50

Albendazole (ABZ) is a benzimidazole derivative with a broad spectrum of activity against human and animal helminthe parasites. ABZ has a very poor aqueous solubility. This study shows that hydroxypropyl ... [more ▼]

Albendazole (ABZ) is a benzimidazole derivative with a broad spectrum of activity against human and animal helminthe parasites. ABZ has a very poor aqueous solubility. This study shows that hydroxypropyl-beta-cyclodextrin (HP-beta-CD) is able to form inclusion complexes with ABZ and that is able to increase its aqueous solubility. A synergistic effect exists between HP-beta-CD and citric acid. The combination of HP-beta-CD (200 mM) and citric acid (50 mM) allows dissolution of more than 1.5 mg of ABZ per ml. The aim of this study is the in vivo evaluation in sheep of a solution of the inclusion complex of ABZ with HP-beta-CD in comparison with a suspension of the same drug. A significant (P<0.05) increase in the relative bioavailability is obtained with the solution containing the ABZ-HP-beta-CD complex as measured by ABZSO plasma levels. The area under the curve (AUC(0--> proportional, variant )) of the solution is 37% higher than that obtained with the suspension. Likewise the peak plasma concentration (C(max)) is twice that of the solution while the time to reach C(max) (T(max)) is reduced. [less ▲]

Detailed reference viewed: 48 (1 ULg)
Full Text
Peer Reviewed
See detailOral calcitonin in the management of osteoarthritis: hope or fantasy ?
Reginster, Jean-Yves ULg; Neuprez, Audrey ULg; Hiligsmann, Mickaël ULg et al

in International Journal of Clinical Rheumatology (2010), 5(1), 53-58

In the mid-1980s, calcitonin was used as a potential treatment for postmenopausal osteoporosis. However, after the results obtained in a pivotal study assessing the antifracture efficacy of the drug ... [more ▼]

In the mid-1980s, calcitonin was used as a potential treatment for postmenopausal osteoporosis. However, after the results obtained in a pivotal study assessing the antifracture efficacy of the drug showed an absence of reduction in nonvertebral fractures, calcitonin has almost completely disappeared from the osteoporosis armomentarium. The development of a new ‘high-tech’ oral formulation of salmon calcitonin and the demonstration, in several in vitro and in vivo models of osteoarthritis, that this drug could exert beneficial effects on the chondrocytes and on the development of experimental osteoarthritis has generated some interest in this old molecule. However, at this stage, results from clinical trials remain inconclusive and caution should be exerted before considering oral calcitonin as a breakthrough in the management of osteoarthritis. [less ▲]

Detailed reference viewed: 47 (4 ULg)
Full Text
Peer Reviewed
See detailOral contraception and cardiovascular risk factors during adolescence
Paulus, Dominique; Saint-Remy, Annie ULg; JeanJean, Michel

in Contraception (2000)

The objective of the present study was to analyze the pattern of oral contraceptive (OC) use in teenagers and to examine the relationship between OC use and other cardiovascular risk factors. The study ... [more ▼]

The objective of the present study was to analyze the pattern of oral contraceptive (OC) use in teenagers and to examine the relationship between OC use and other cardiovascular risk factors. The study was conducted in 24 Belgian secondary schools. Most students (1526 adolecents aged 12-17 years) agreed to participate (participation rate: 83.6%). Smoking, physical activity habits, menarche, and OC use were assessed by a self-administered questionnaire. Total cholesterol level, blood pressure and anthropometric measurements were also measured. Fourteen per cent of mature girls (14%, n=92) were OC users. Two-thirds of them (66.3%, n=61) were taking OC which contained either gestodene or desogestrel. Blood pressure and BMI were similar for OC users and non-users. Total cholesterol level was significantly higher in OC users than in non-users (191 mg/dL versus 172 mg/dL). Logistic regression model confirmed the significant influence of OC use on total cholesterol level (OR=3.08). OC users were also often smokers (39% versus 20% for non-users). In conclusion, the present study has found significant relationship between OC use and cardiovascular risk factors i.e., high total cholesterol and smoking. The first implication is a need for further research on lipoprotein profile in young OC users. Secondly, the combined use of OC and smoking in teenagers calls for preventive actions. [less ▲]

Detailed reference viewed: 15 (2 ULg)
Full Text
See detailOral contraception and lipid peroxidation
De Groote, D.; Pincemail, Joël ULg; Defraigne, Jean-Olivier ULg et al

in Clinical Chemistry (2007, June), 53(6, Suppl. S), 30-30

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailOral exposure to culture material extract containing fumonisins predisposes swine to the development of pneumonitis caused by Pasteurella multocida.
Halloy, David J; Gustin, Pascal ULg; Bouhet, Sandrine et al

in Toxicology (2005), 213(1-2), 34-44

Fumonisin B(1) (FB(1)) is a mycotoxin produced by Fusarium verticillioides and F. proliferatum that commonly occurs in maize. In swine, consumption of contaminated feed induces liver damage and pulmonary ... [more ▼]

Fumonisin B(1) (FB(1)) is a mycotoxin produced by Fusarium verticillioides and F. proliferatum that commonly occurs in maize. In swine, consumption of contaminated feed induces liver damage and pulmonary edema. Pasteurella multocida is a secondary pathogen, which can generate a respiratory disorder in predisposed pigs. In this study, we examined the effect of oral exposure to fumonisin-containing culture material on lung inflammation caused by P. multocida. Piglets received by gavage a crude extract of fumonisin, 0.5mg FB(1)/kg body weight/day, for 7 days. One day later, the animals were instilled intratracheally with a non toxin producing type A strain of P. multocida and followed up for 13 additional days. Pig weight and cough frequency were measured throughout the experiment. Lung lesions, bronchoalveolar lavage fluid (BALF) cell composition and the expression of inflammatory cytokines were evaluated at the autopsy. Ingestion of fumonisin culture material or infection with P. multocida did not affect weight gain, induced no clinical sign or lung lesion, and only had minimal effect on BALF cell composition. Ingestion of mycotoxin extract increased the expression of IL-8, IL-18 and IFN-gamma mRNA compared with P. multocida infection that increased the expression of TNF-alpha. The combined treatment with fumonisin culture material and P. multocida delayed growth, induced cough, and increased BALF total cells, macrophages and lymphocytes. Lung lesions were significantly enhanced in these animals and consisted of subacute interstitial pneumonia. TNF-alpha, IFN-gamma and IL-18 mRNA expression was also increased. Taken together, our data showed that fumonisin culture material is a predisposing factor to lung inflammation. These results may have implications for humans and animals consuming FB(1) contaminated food or feed. [less ▲]

Detailed reference viewed: 42 (1 ULg)
Full Text
Peer Reviewed
See detailOral glucose tolerance tests in schizophrenic patients treated with antipsychotics
De Hert, Marc; Van Eyck, Dominique; Hermans, Gilberte ULg et al

in International Journal of Neuropsychopharmacology (2004, June), 7(Suppl. 1), 424

Objective. –A recent consensus conference has proposed guidelines for the monitoring for diabetes in patients with schizophrenia and also identifies the need of long-term prospective studies. Method. – A ... [more ▼]

Objective. –A recent consensus conference has proposed guidelines for the monitoring for diabetes in patients with schizophrenia and also identifies the need of long-term prospective studies. Method. – A large scale prospective study on metabolic risks of antipsychotic medication is currently ongoing. At baseline, patients get a full laboratory screening, ECG and an oral glucose tolerance test (OGTT). Baseline data on 100 non-diabetic patients at study inclusion and stable on medication for at least 6 months are presented. Results. – Glucose abnormalities are found in 22% of patients at baseline.A monitoring protocol based only on fasting glucose would not have detected 63.6% of these patients with classifiable glucose abnormalities in our sample. Fasting insulin and measures for insulin resistance have a high predictive value for abnormalities late in the OGTT. Conclusion. – Already at baseline, metabolic problems are frequently present in patients with schizophrenia treated with antipsychotics. Adding assessment of fasting insulin in a monitoring protocol improves detection of glucose abnormalities late in an OGTT. [less ▲]

Detailed reference viewed: 32 (6 ULg)
Full Text
Peer Reviewed
See detailOral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics?
De Hert, Marc; Van Eyck, Dominique; Hanssens, Linda et al

in European Psychiatry (2006), 21(4), 224-226

Objective. - A recent consensus conference has proposed guidelines for the monitoring for diabetes in patients with schizophrenia and also identifies the need of long-term prospective studies. Method. - A ... [more ▼]

Objective. - A recent consensus conference has proposed guidelines for the monitoring for diabetes in patients with schizophrenia and also identifies the need of long-term prospective studies. Method. - A large scale prospective study on metabolic risks of antipsychotic medication is currently ongoing. At baseline, patients get a full laboratory screening, ECG and an oral glucose tolerance test (OGTT). Baseline data on 100 non-diabetic patients at study inclusion and stable on medication for at least 6 months are presented. Results. - Glucose abnormalities are found in 22% of patients at baseline, A monitoring protocol based only on fasting glucose would not have detected 63.6% of these patients with classifiable glucose abnormalities in our sample. Fasting insulin and measures for insulin resistance have a high predictive value for abnormalities late in the OGTT. Conclusion. - Already at baseline, metabolic problems are frequently present in patients with schizophrenia treated with antipsychotics. Adding assessment of fasting insulin in a monitoring protocol improves detection of glucose abnormalities late in an OGTT. (c) 2005 Elsevier SAS. All rights reserved. [less ▲]

Detailed reference viewed: 23 (1 ULg)
Full Text
Peer Reviewed
See detailOral ibandronate (150 mg) continues to be effective and well tolerated when administered monthly: the mobile study long-term extension
Stakkestad, J. A.; Lorenc, R.; Czerwinski, E. et al

in Osteoporosis International (2007, March), 18(Suppl.1), 135-136

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailOral ibandronate (150mg) administered monthly provides similar improvements in hip bone mineral density as oral alendronate (70mg) administered weekly in postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Borges, Joao LC; Recknor, Chris et al

in Arthritis and Rheumatism (2007, September), 56(number 9 (suppl.)), 611

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailOral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis
Reginster, Jean-Yves ULg

in Expert Opinion on Pharmacotherapy (2005), 6(13), 2301-2313

Osteoporosis is a severe condition, associated with significant disability as a result of fragility fractures and increased mortality. Oral bisphosphonates effectively reduce the risk of osteoporotic ... [more ▼]

Osteoporosis is a severe condition, associated with significant disability as a result of fragility fractures and increased mortality. Oral bisphosphonates effectively reduce the risk of osteoporotic fracture and are generally well tolerated. Unfortunately, patient outcomes are often compromised by suboptimal therapeutic adherence. In other disease areas, reduced dosing frequency has been shown to improve therapeutic adherence. A positive impact for adherence has been observed with a reduction in the bisphosphonate dosing frequency from daily to weekly. However, overall adherence remains suboptimal. lbandronate is a potent nitrogen-containing bisphosphonate specifically designed for less frequent than weekly administration, without compromise for efficacy or tolerability. This article reviews the pharmacology, efficacy and tolerability of oral ibandronate when administered with extended dosing intervals in postmenopausal osteoporosis. [less ▲]

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailOral monthly ibandronate decrease bone turnover in postmenopausal women with low bone mass: results from the monthly oral pilot study (MOPS)
Reginster, Jean-Yves ULg; Wiese, C.; Wilson, K. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 5

Detailed reference viewed: 34 (0 ULg)